|
1
|
Veliz I, Loo Y, Castillo O, Karachaliou N,
Nigro O and Rosell R: Advances and challenges in the molecular
biology and treatment of glioblastoma-is there any hope for the
future? Ann Transl Med. 3:72015.PubMed/NCBI
|
|
2
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al
Cancer Genome Atlas Research Network: Integrated genomic analysis
identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fan TY, Wang H, Xiang P, Liu YW, Li HZ,
Lei BX, Yu M and Qi ST: Inhibition of EZH2 reverses
chemotherapeutic drug TMZ chemosensitivity in glioblastoma. Int J
Clin Exp Pathol. 7:6662–6670. 2014.PubMed/NCBI
|
|
4
|
Network CGAR; Cancer Genome Atlas Research
Network: Comprehensive genomic characterization defines human
glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lo HW: EGFR-targeted therapy in malignant
glioma: Novel aspects and mechanisms of drug resistance. Curr Mol
Pharmacol. 3:37–52. 2010. View Article : Google Scholar
|
|
6
|
Quick A, Patel D, Hadziahmetovic M,
Chakravarti A and Mehta M: Current therapeutic paradigms in
glioblastoma. Rev Recent Clin Trials. 5:14–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eyüpoglu IY and Savaskan NE: Epigenetics
in Brain Tumors: HDACs Take Center Stage. Curr Neuropharmacol.
14:48–54. 2016. View Article : Google Scholar :
|
|
8
|
Ferreira WA, Pinheiro DR, Costa Junior CA,
Rodrigues-Antunes S, Araújo MD, Leão Barros MB, Teixeira AC, Faro
TA, Burbano RR, Oliveira EH, et al: An update on the epigenetics of
glioblastomas. Epigenomics. 8:1289–1305. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gusyatiner O and Hegi ME: Glioma
epigenetics: From subclassification to novel treatment options.
Semin Cancer Biol. 51:50–58. 2018. View Article : Google Scholar
|
|
10
|
Kreth S, Thon N and Kreth FW: Epigenetics
in human gliomas. Cancer Lett. 342:185–192. 2014. View Article : Google Scholar
|
|
11
|
Yong RL and Tsankova NM: Emerging
interplay of genetics and epigenetics in gliomas: A new hope for
targeted therapy. Semin Pediatr Neurol. 22:14–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen J, Zhang M, Zhang X, Fan L, Liu P, Yu
L, Cao X, Qiu S and Xu Y: EZH2 inhibitor DZNep modulates microglial
activation and protects against ischaemic brain injury after
experimental stroke. Eur J Pharmacol. 857:1724522019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Atadja P: Development of the pan-DAC
inhibitor panobinostat (LBH589): Successes and challenges. Cancer
Lett. 280:233–241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gall Trošelj K, Novak Kujundzic R and
Ugarkovic D: Polycomb repressive complex's evolutionary conserved
function: The role of EZH2 status and cellular background. Clin
Epigenetics. 8:552016. View Article : Google Scholar
|
|
15
|
Rao ZY, Cai MY, Yang GF, He LR, Mai SJ,
Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, et al: EZH2 supports
ovarian carcinoma cell invasion and/or metastasis via regulation of
TGF-beta1 and is a predictor of outcome in ovarian carcinoma
patients. Carcinogenesis. 31:1576–1583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li K, Liu C, Zhou B, Bi L, Huang H, Lin T
and Xu K: Role of EZH2 in the growth of prostate cancer stem cells
isolated from LNCaP cells. Int J Mol Sci. 14:11981–11993. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Yu X, Chen L, Zhang Z and Feng S:
EZH2 overexpression is associated with poor prognosis in patients
with glioma. Oncotarget. 8:565–573. 2017.
|
|
18
|
Crea F, Fornaro L, Bocci G, Sun L, Farrar
WL, Falcone A and Danesi R: EZH2 inhibition: Targeting the
crossroad of tumor invasion and angiogenesis. Cancer Metastasis
Rev. 31:753–761. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hayden A, Johnson PW, Packham G and Crabb
SJ: S-adenosylhomocysteine hydrolase inhibition by
3-deazaneplanocin A analogues induces anti-cancer effects in breast
cancer cell lines and synergy with both histone deacetylase and
HER2 inhibition. Breast Cancer Res Treat. 127:109–119. 2011.
View Article : Google Scholar
|
|
20
|
Kemp CD, Rao M, Xi S, Inchauste S, Mani H,
Fetsch P, Filie A, Zhang M, Hong JA, Walker RL, et al: Polycomb
repressor complex-2 is a novel target for mesothelioma therapy.
Clin Cancer Res. 18:77–90. 2012. View Article : Google Scholar
|
|
21
|
Suvà ML, Riggi N, Janiszewska M,
Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino
D, Cironi L, et al: EZH2 is essential for glioblastoma cancer stem
cell maintenance. Cancer Res. 69:9211–9218. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Crea F, Hurt EM, Mathews LA, Cabarcas SM,
Sun L, Marquez VE, Danesi R and Farrar WL: Pharmacologic disruption
of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor
progression in prostate cancer. Mol Cancer. 10:402011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiba T, Suzuki E, Negishi M, Saraya A,
Miyagi S, Konuma T, Tanaka S, Tada M, Kanai F, Imazeki F, et al:
3-Deazaneplanocin A is a promising therapeutic agent for the
eradication of tumor-initiating hepatocellular carcinoma cells. Int
J Cancer. 130:2557–2567. 2012. View Article : Google Scholar
|
|
24
|
Smits M, Mir SE, Nilsson RJ, van der Stoop
PM, Niers JM, Marquez VE, Cloos J, Breakefield XO, Krichevsky AM,
Noske DP, et al: Down-regulation of miR-101 in endothelial cells
promotes blood vessel formation through reduced repression of EZH2.
PLoS One. 6:e162822011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamagishi M and Uchimaru K: Targeting EZH2
in cancer therapy. Curr Opin Oncol. 29:375–381. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yan KS, Lin CY, Liao TW, Peng CM, Lee SC,
Liu YJ, Chan WP and Chou RH: EZH2 in Cancer Progression and
Potential Application in Cancer Therapy: A Friend or Foe? Int J Mol
Sci. 18:182017. View Article : Google Scholar
|
|
27
|
Kim KH and Roberts CW: Targeting EZH2 in
cancer. Nat Med. 22:128–134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu C, Friday BB, Yang L, Atadja P, Wigle
D, Sarkaria J and Adjei AA: Mitochondrial Bax translocation
partially mediates synergistic cytotoxicity between histone
deacetylase inhibitors and proteasome inhibitors in glioma cells.
Neuro Oncol. 10:309–319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berghauser Pont LM, Kleijn A, Kloezeman
JJ, van den Bossche W, Kaufmann JK, de Vrij J, Leenstra S, Dirven
CM and Lamfers ML: The HDAC Inhibitors Scriptaid and LBH589
Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced
Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells. PLoS
One. 10:e01270582015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee EQ, Reardon DA, Schiff D, Drappatz J,
Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML,
et al: Phase II study of panobinostat in combination with
bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro
Oncol. 17:862–867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pont LM, Naipal K, Kloezeman JJ,
Venkatesan S, van den Bent M, van Gent DC, Dirven CM, Kanaar R,
Lamfers ML and Leenstra S: DNA damage response and anti-apoptotic
proteins predict radiosensitization efficacy of HDAC inhibitors
SAHA and LBH589 in patient-derived glioblastoma cells. Cancer Lett.
356(2 Pt B): 525–535. 2015. View Article : Google Scholar
|
|
32
|
Singleton WG, Collins AM, Bienemann AS,
Killick-Cole CL, Haynes HR, Asby DJ, Butts CP, Wyatt MJ, Barua NU
and Gill SS: Convection enhanced delivery of panobinostat
(LBH589)-loaded pluronic nano-micelles prolongs survival in the F98
rat glioma model. Int J Nanomedicine. 12:1385–1399. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yao ZG, Li WH, Hua F, Cheng HX, Zhao MQ,
Sun XC, Qin YJ and Li JM: LBH589 Inhibits Glioblastoma Growth and
Angiogenesis Through Suppression of HIF-1α Expression. J
Neuropathol Exp Neurol. 76:1000–1007. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Y and Seto E: HDACs and HDAC Inhibitors
in Cancer Development and Therapy. Cold Spring. Harb Perspect Med.
6:62016.
|
|
35
|
De Souza C and Chatterji BP: HDAC
Inhibitors as Novel Anti-Cancer Therapeutics. Recent Patents
Anticancer Drug Discov. 10:145–162. 2015. View Article : Google Scholar
|
|
36
|
Turtoi A, Peixoto P, Castronovo V and
Bellahcène A: Histone deacetylases and cancer-associated
angiogenesis: Current understanding of the biology and clinical
perspectives. Crit Rev Oncog. 20:119–137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aum DJ, Kim DH, Beaumont TL, Leuthardt EC,
Dunn GP and Kim AH: Molecular and cellular heterogeneity: The
hallmark of glioblastoma. Neurosurg Focus. 37:E112014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Friedmann-Morvinski D: Glioblastoma
heterogeneity and cancer cell plasticity. Crit Rev Oncog.
19:327–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Greco WR, Bravo G and Parsons JC: The
search for synergy: A critical review from a response surface
perspective. Pharmacol Rev. 47:331–385. 1995.PubMed/NCBI
|
|
40
|
Goldin A and Mantel N: The employment of
combinations of drugs in the chemotherapy of neoplasia: A review.
Cancer Res. 17:635–654. 1957.PubMed/NCBI
|
|
41
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Berenbaum MC: Synergy, additivism and
antagonism in immunosuppression. A critical review Clin Exp
Immunol. 28:1–18. 1977.
|
|
43
|
Loewe S: Marginal notes on the
quantitative pharmacology of combined drugs. Arzneimittelforschung.
9:449–456. 1959.In German. PubMed/NCBI
|
|
44
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Foucquier J and Guedj M: Analysis of drug
combinations: Current methodological landscape. Pharmacol Res
Perspect. 3:e001492015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chou T and Martin N: CompuSyn Software for
Drug Combinations and for General Dose Effect Analysis. ComboSyn,
Inc.; Paramus, NJ: 2007
|
|
48
|
Johannessen TC, Hasan-Olive MM, Zhu H,
Denisova O, Grudic A, Latif MA, Saed H, Varughese JK, Røsland GV,
Yang N, et al: Thioridazine inhibits autophagy and sensitizes
glioblastoma cells to temozolomide. Int J Cancer. 144:1735–1745.
2019. View Article : Google Scholar
|
|
49
|
Smits M, Nilsson J, Mir SE, van der Stoop
PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J,
Krichevsky AM, et al: miR-101 is down-regulated in glioblastoma
resulting in EZH2-induced proliferation, migration, and
angiogenesis. Oncotarget. 1:710–720. 2010. View Article : Google Scholar
|
|
50
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)). Method Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
51
|
Lee SY: Temozolomide resistance in
glioblastoma multiforme. Genes Dis. 3:198–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fiskus W, Rao R, Balusu R, Ganguly S, Tao
J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, et al:
Superior efficacy of a combined epigenetic therapy against human
mantle cell lymphoma cells. Clin Cancer Res. 18:6227–6238. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fiskus W, Wang Y, Sreekumar A, Buckley KM,
Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al:
Combined epigenetic therapy with the histone methyltransferase EZH2
inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor
panobinostat against human AML cells. Blood. 114:2733–2743. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Takashina T, Kinoshita I, Kikuchi J,
Shimizu Y, Sakakibara-Konishi J, Oizumi S, Nishimura M and
Dosaka-Akita H: Combined inhibition of EZH2 and histone
deacetylases as a potential epigenetics therapy for non-small-cell
lung cancer cells. Cancer Sci. 107:955–962. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ding L, Chen S, Liu P, Pan Y, Zhong J,
Regan KM, Wang L, Yu C, Rizzardi A, Cheng L, et al: CBP loss
cooperates with PTEN haploinsufficiency to drive prostate cancer:
Implications for epigenetic therapy. Cancer Res. 74:2050–2061.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Çıtışlı V, Dodurga Y, Eroğlu C, Seçme M,
Avcı CB and Şatıroğlu-Tufan NL: Temozolomide may induce cell cycle
arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma
cells. Tumour Biol. 36:6765–6772. 2015. View Article : Google Scholar
|
|
57
|
Pawlowska E, Szczepanska J, Szatkowska M
and Blasiak J: An Interplay between Senescence, Apoptosis and
Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and
Therapeutic Perspective. Int J Mol Sci. 19:32018. View Article : Google Scholar
|
|
58
|
Perazzoli G, Prados J, Ortiz R, Caba O,
Cabeza L, Berdasco M, Gónzalez B and Melguizo C: Temozolomide
Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR,
P-Glycoprotein and CD133 Expression. PLoS One. 10:e01401312015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Dong J, Meng X, Li S, Chen Q, Shi L, Jiang
C and Cai J: Risk of adverse vascular events in patients with
malignant glioma treated with bevacizumab plus irinotecan: A
systematic review and meta-analysis. World Neurosurg.
130:e236–e243. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang R, Banik NL and Ray SK: Differential
sensitivity of human glioblastoma LN18 (PTEN-positive) and A172
(PTEN-negative) cells to Taxol for apoptosis. Brain Res.
1239:216–225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Patyka M, Sharifi Z, Petrecca K, Mansure
J, Jean-Claude B and Sabri S: Sensitivity to PRIMA-1MET is
associated with decreased MGMT in human glioblastoma cells and
glioblastoma stem cells irrespective of p53 status. Oncotarget.
7:60245–60269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Koul D, Wang S, Wu S, Saito N, Zheng S,
Gao F, Kaul I, Setoguchi M, Nakayama K, Koyama K, et al:
Preclinical therapeutic efficacy of a novel blood-brain
barrier-penetrant dual PI3K/mTOR inhibitor with preferential
response in PI3K/PTEN mutant glioma. Oncotarget. 8:21741–21753.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hill VK, Kim JS, James CD and Waldman T:
Correction of PTEN mutations in glioblastoma cell lines via
AAV-mediated gene editing. PLoS One. 12:e01766832017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Muñoz J, Inda MM, Lázcoz P, Zazpe I, Fan
X, Alfaro J, Tuñón T, Rey JA and Castresana JS: Promoter
Methylation of RASSF1A Associates to Adult Secondary Glioblastomas
and Pediatric Glioblastomas. ISRN Neurol. 2012:5765782012.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
de la Rosa J, Urdiciain A, Aznar-Morales
JJ, Meléndez B, Rey JA, Idoate MA and Castresana JS: Panobinostat
and its combination with 3-deazaneplanocin-A induce apoptosis and
inhibit In vitro tumorigenesis and metastasis in GOS-3 glioblastoma
cell lines. Cancer Transl Med. 4:39–47. 2018. View Article : Google Scholar
|
|
66
|
Forget KJ, Tremblay G and Roucou X: p53
Aggregates penetrate cells and induce the co-aggregation of
intracellular p53. PLoS One. 8:e692422013. View Article : Google Scholar : PubMed/NCBI
|
